Abiochem's steviol glycosides, have been selected for the authoritative Shanghai Innovative Product Recommendation Catalog. The product leverages an exclusive enzymatic conversion method to achieve a breakthrough purity of 98%-99%, overcoming the limitations of traditional stevia extraction. It holds dual-market recognition as the only product of its kind approved by China's National Health Commission and by the U.S. FDA GRAS, with applications spanning beverages, dairy, confectionery, and baked goods....

Abiochem has been solidly selected for the 2025 Shanghai Hardcore Technology Enterprises TOP100 List and Industry Standards TOP50, recognized for its breakthrough innovations in synthetic biology. Supported by eight core technology platforms, the company enables full-chain R&D from gene editing to scale-up production, delivering solutions for biomedicine, green agriculture, and life health. This achievement, validated by authoritative bodies, underscores Abiochem's role in driving high-quality industrial development within Shanghai's innovation ecosystem....

Abiochem has been selected for the national biomanufacturing pilot platform, a joint initiative by MIIT and NDRC, to bridge the gap from lab to industrialization in synthetic biology. The platform focuses on food industry applications, including novel ingredients and additives ('Three New Foods'), fostering innovation, health, and sustainability, and supporting China's high-quality industrial development.

SDIC JULI has invested RMB 450 million in synthetic biology leader Abiochem, known for its complete 'enzyme-to-product' biomanufacturing platform and breakthrough functional ingredients like HMOs. The partnership will accelerate R&D in non-grain feedstocks and biomanufacturing scale-up.

Abiochem's ergothioneine, a life health product, has achieved U.S. Self-GRAS certification, validating its safety and quality in raw materials, processes, and control. Using synthetic biology, it offers high purity, safety, and large-scale production, supporting global expansion and domestic demand growth.

Shanghai, August 6, 2025 — Agilent Technologies Inc. (NYSE: A) and Abiochem Biotechnology (Group) Co., Ltd. ("Abiochem") today inaugurated the "Joint Innovation Laboratory for Synthetic Biology" at Abiochem's R&D center. The ceremony was attended by Ding Hao, Agilent Assistant Vice President and General Manager of Biopharma Business & East China Instrument Sales, and Qu Xudong, Co-founder of Abiochem, leading executive delegations from both parties. The laboratory will leverage complementary strengths to advance high-throughput synthetic biology design/screening platforms, optimize quality control for biosynthetic processes, and co-develop application cases with published outcomes to accelerate industry innovation. As a synthetic biology leader, Abiochem focuses on industrial applications across biopharma, green agriculture, and...

Recently, the Ministry of Industry and Information Technology released the "2024 Outstanding Cases for Future Industry Development." Abiochem's project "Biosynthesis and Formulation Technology of Natural Sweetener Steviol Glycosides" was selected as a future health exemplary case, establishing a benchmark for innovative application of synthetic biology in healthy foods.   Amid China's world-leading diabetic population (141 million in 2021 per IDF data) and sugar-restriction policies, steviol glycoside Reb M - a high-intensity, low-calorie natural sweetener faces limited adoption due to costly plant extraction. Abiochem pioneered an efficient enzymatic conversion method that drastically reduces costs while resolving application challenges like solubility and taste. Approved by China's National Health Commission in March 2024 as a novel food i...

Beijing, March 13, 2024 - National Health Commission of the People’s Republic of China issued an announcement approving several food additives. Among them, Abiochem's independently developed Enzymatically Produced Steviol Glycosides has successfully passed the approval process.

Shanghai, November 16th, 2022 – Recently, Abiochem announced its nomination as one of the forth batch national-level “little giant” enterprises, published by the Ministry of Industry and Information Technology (MIIT).

SHANGHAI, September 26, 2021 - Abiochem has cooperated with a leading diabetes company，Tonghua Dongbao Pharmaceutical Co., Ltd. （600867.SH) to produce a generic version of Sitagliptin, and gets approved by CDC (Chinese Center for Disease Control and Prevention) recently. This drug is the first domestic generic drug manufactured based on "non-hydrolase" biosynthetic methods, opening up a new chapter in biosynthetic pharmaceuticals.

Chongqing, July 21, 2022 – Abiochem today announced the opening of a new production base in Changshou District, Chongqing Province.

SHANGHAI, July 29, 2022 – Abiochem announced its selection as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2021. Abiochem was chosen for its innovative R&D ability and industrialization progress in synthetic biology.